UTAH MEDICAL PRODUCTS INC
UTMDNasdaq
$69.80
↓ -2.7%Jul 17 close · end-of-day
Price
1Y↑ +26.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$222.3M
Enterprise Value
$135.1M
P/E
20.7
P/S
5.9
P/B
1.8
EV/EBITDA
11.6
PEG
—
FCF Yield
5.9%
Dividend Yield
—
Revenue (TTM)
$37.5M
Net Income (TTM)
—
Free Cash Flow (TTM)
$13.0M
Gross Margin
57.9%
Operating Margin
28.8%
Net Margin
—
ROE
—
ROIC
26.3%
Debt / Equity
0.0
Net Cash
$87.2M
Return 1Y
+27.1%
Company profile
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets.
- CEO
- Kevin L. Cornwell
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 180
- Website
- utahmed.com
Earnings
UTMD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$8.7M↓ -10.2%
Diluted EPS$0.82↓ -10.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $49.1M | $52.3M | $50.2M | $40.9M | $38.5M |
| Gross profit | $25.5M | $30.9M | $32.2M | $30.0M | $24.1M | $22.0M |
| Operating income | $13.7M | $18.9M | $19.8M | $16.8M | $13.6M | $11.4M |
| Net income | — | — | — | — | — | — |
| Diluted EPS | $2.94 | $4.04 | $4.52 | $4.57 | $3.96 | $3.48 |
| Operating cash flow | $20.1M | $21.2M | $21.1M | $22.3M | $14.8M | $14.7M |
| Free cash flow | $19.3M | $20.7M | $20.3M | $21.6M | $14.6M | $14.3M |
| Gross margin | 60.6% | 63.0% | 61.6% | 59.8% | 59.0% | 57.1% |
| Operating margin | 32.5% | 38.5% | 37.9% | 33.4% | 33.2% | 29.6% |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4M | $10.0M | $9.2M | $9.7M | $10.0M | $9.8M | $9.0M | $8.7M |
| Gross profit | $6.3M | $5.8M | $5.3M | $5.5M | $5.6M | $5.6M | $5.3M | $5.3M |
| Operating income | $3.4M | $3.3M | $2.9M | $3.2M | $3.2M | $2.6M | $2.4M | $2.6M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | $0.98 | $1.03 | $0.86 | $0.92 | $0.94 | $0.82 | $0.80 | $0.82 |
| Operating cash flow | $2.8M | $3.9M | $2.9M | $4.5M | $2.9M | $3.9M | $3.5M | $3.1M |
| Free cash flow | $2.7M | $3.8M | $2.9M | $4.3M | $2.8M | $3.9M | $3.4M | $3.0M |
| Gross margin | 60.1% | 58.0% | 58.1% | 57.0% | 56.2% | 57.1% | 58.2% | 60.6% |
| Operating margin | 33.1% | 33.4% | 32.0% | 32.5% | 32.1% | 26.6% | 27.0% | 29.4% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Apr 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.